As PTPN1/2 negatively regulates inflammation and PTPN1/2 inhibition is currently being explored for immunotherapy against cancer, it would be pertinent to assess the impact of PTPN1/2 inhibition on inflammation within the context of DMD and steroid treatment (Manguso et al, 2017; Baumgartner et al, 2023). This evidence concerns the gene PTPN1 and cancer.